A Phase 2 interventional study of TS-172 10mg bid and TS-172 30mg bid in Hyperphosphatemia Patients on Hemodialysis, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
This study's enrollment of 326 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Browse Hyperphosphatemia studies →Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive TS-172 10 mg bid.
Drug: TS-172 10mg bid
Patients receive TS-172 30 mg bid.
Drug: TS-172 30mg bid
Patients receive TS-172 60 mg bid.
Drug: TS-172 60mg bid
Patients receive TS-172 20 mg tid.
Drug: TS-172 20mg tid
Patients receive placebo.
Drug: Placebo
oral administration of TS-172 10 mg bid
oral administration of TS-172 30 mg bid
oral administration of TS-172 60 mg bid
oral administration of TS-172 20 mg tid
oral administration of placebo
Change from baseline in serum concentration of phosphorus
Time frame: Week 4
Achievement ratio of patients with the target serum concentration of phosphorus
Time frame: Up to Week 4
Concentration of corrected serum calcium
Time frame: Up to Week 4
Serum calcium times phosphorus product
Time frame: Up to Week 4
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TS-172
Taisho Pharmaceutical Co., Ltd. →